

The Clinical Case for providing stop smoking support to Rheumatic Disease Patients

Why intervene in secondary care?

1. Hospital patients are more receptive to 'Very Brief Advice' (VBA) and an offer of support to stop smoking, as they are often experiencing a period of heightened motivation
2. Giving VBA to a hospital patient (the '3 A's': Ask, Advise, Act) can also encourage compliance to the smokefree hospital policy, and highlight any need for withdrawal management. Providing Nicotine Replacement Therapy (NRT) to a patient during a period of forced abstinence, will ease nicotine withdrawal symptoms
3. Stopping smoking can lead to significant health benefits, and reduce post-operative complications and improve recovery time

What is the aim of this 'clinical case' document?

The aim of this document is to provide clinical support for hospital staff in terms of supporting patients to stop smoking, even if this is just for a period of forced abstinence whilst in hospital. Being in hospital provides an opportune moment to intervene and provide both brief advice and support to stop smoking; including making a referral on to local stop smoking support. There are many benefits for a patient if they have temporary abstinence from smoking, including a shorter time for recovery and this can often stimulate a full attempt to stop smoking.

What is the relationship between smoking and rheumatic disease?

Cigarette smoking has been identified as an independent risk factor of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)^{1,2,3,4,5,6}; and is associated with the severity of the disease.^{7,2}

Smoking is linked with disease processes that predispose rheumatoid arthritis patients to other conditions:

- Smoking increases rheumatoid factor and alters immune function in the lungs that causes a predisposition to cardiovascular disease.^{6,8}
- Smoking increases risk of cancer^{6,1}, and one large cohort study found slightly increased overall risk of cancer, 20–50% increased risk of smoking-related cancer.⁹

The Clinical Case for providing stop smoking support to Rheumatic Disease Patients

What are the health benefits of stopping smoking for rheumatoid arthritis patients?

The risk of RA remains elevated until 10–20 years after stopping smoking.^{10,3} In addition, RA and SLE patients are at greater risk of premature death than the general population mainly due to cardiovascular disease, which is promoted by the disease itself.^{1,11,12} Successfully stopping smoking will not only benefit a patient's long term health by reducing the risk of developing smoking related disease,¹³ but abstinence from smoking may also help a patient to recover quicker by eliminating the acute effects of smoking on the body. The benefits of stopping smoking both in terms of general outcomes and disease-specific outcomes are well evidenced.

Main acute effects of smoking on the body (estimated time of recovery, if known)

- Increase in sympathetic tone leading to an increase in blood pressure, heart rate and peripheral vasoconstriction leading to an increased demand for oxygen and cardiac function.¹⁴
(24 – 48 hours)
- Formation of carboxyhaemoglobin leading to a reduction in oxygen delivery to the tissues.^{15,16,17}
(8 – 24 hours)
- Formation of carboxymyoglobin leading to a reduction in oxygen storage in the muscles.¹⁸
(8 – 24 hours)
- Increase in red blood cell production, which leads to an increase in blood viscosity, a decrease in tissue perfusion, a decrease in oxygen delivery to the tissues and potentiation of thrombotic process.^{19,20}
- Hypersecretion of mucus, narrowing of the small airways, decrease in ciliary function and change in mucus rheology leading to a decrease in mucociliary transport.^{19,20} **(12 – 72 hours)**
- Changes in functioning of a range of immune cells (pro- and anti-inflammatory cytokines, white blood cells, immunoglobulins) which lead to decreased immunity and are associated with atherosclerosis.^{19,20} **(1 week – 2 months)**
- Induction of hepatic enzymes which increases drug metabolism through both pharmacokinetic and pharmacodynamic mechanisms.²¹ **(6 – 8 weeks)**

The Clinical Case for providing stop smoking support to Rheumatic Disease Patients**General health benefits of stopping smoking¹**

- Within 20 minutes blood pressure drops to the level it was before the last cigarette.
- Within 8 hours carbon monoxide levels in the blood return to normal.
- Within 24 hours the chance of a heart attack decreases.
- Within 2 weeks to 3 months circulation improves and lung function increases.
- Within 1 to 9 months lungs regain normal ciliary function, reducing infection risk.
- By 10 years the risk of lung cancer is approximately half of a smoker. The risk of cancers of the mouth, throat, bladder, kidney and pancreas also decrease.

Health benefits of stopping smoking for RA and SLE patients

Improvements in disease activity:

- For current smokers there was no improvement of disease activity depending on disease duration. The trend of disease improvement was similar in ex-smokers and never-smokers²³
- Non-smokers and light smokers (with <20 pack-years) had a two fold higher risk to reach ACR improvement²⁴

The Clinical Case for providing stop smoking support to Rheumatic Disease Patients

Providing 'Very Brief Advice' to hospital patients: the '3 A's'

Providing a stop smoking intervention to a hospital patient is proven to be effective regardless of the reason for admission.²⁵ One study concluded that patients with SLE require careful management to stop smoking among other behavioural changes to reduce the risk of coronary heart disease.²⁶ Offering VBA is the single most cost effective and clinically proven preventative action a healthcare professional can take²⁷ and it is important to keep giving advice at every opportunity, as smokers may take several attempts to stop smoking successfully.²⁸ In addition, by referring a patient to a local stop smoking service, they are four times more likely to stop smoking.²⁹

Research shows that 95% of patients expect to be asked about smoking and a short intervention can make all the difference.^{30,31} The '3 A's' 30 second approach to giving 'very brief advice' are as follows:

ASK and record smoking status

ADVISE the patient of the personal health benefits of stopping smoking

ACT on the patient's response

- prescribe NRT for patients in withdrawal
- monitor withdrawal and adjust pharmacotherapy accordingly
- refer to local stop smoking service

How was this information sheet put together?

This information is a summary of the current scientific evidence on the association between cigarette smoking and rheumatic disease. Studies were found by searching MEDLINE and EMBASE using combined exploded subject headings of 'rheumatology' and 'tobacco use cessation' from 01/1990 – 07/2011 and by searching the US surgeon general on the health benefits of smoking cessation.³² Evidence has been included in this summary from cohort studies, randomised controlled trials and reviews only.

The Clinical Case for providing stop smoking support to Rheumatic Disease Patients

References

1. Carmona, L., M. Cross, B. Williams, M. Lassere, and L. March. 2010. "Rheumatoid arthritis." *Best Pract Res Clin Rheumatol* 24(6):733–45.
2. Vittecoq, O., T. Lequerre, V. Goeb, X. Le Loet, T. A. Abdesselam, and N. Klemmer. 2008. "Smoking and inflammatory diseases." *Best Pract Res Clin Rheumatol* 22(5):923–35.
3. Stolt, P., C. Bengtsson, B. Nordmark, S. Lindblad, I. Lundberg, L. Klareskog, and L. Alfredsson. 2003. "Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases." *Ann Rheum Dis* 62(9):835–41.
4. Criswell, L. A., L. A. Merlino, J. R. Cerhan, T. R. Mikuls, A. S. Mudano, M. Burma, A. R. Folsom, and K. G. Saag. 2002. "Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: results from the Iowa Women's Health Study." *Am J Med* 112(6):465–71.
5. Reckner Olsson, A., T. Skogh, and G. Wingren. 2001. "Comorbidity and lifestyle, reproductive factors, and environmental exposures associated with rheumatoid arthritis." *Ann Rheum Dis* 60(10):934–9.
6. Albano, S. A., E. Santana-Sahagun, and M. H. Weisman. 2001. "Cigarette smoking and rheumatoid arthritis." *Semin Arthritis Rheum* 31(3):146–59.
7. Goodson, N. J., T. M. Farragher, and D. P. Symmons. 2008. "Rheumatoid factor, smoking, and disease severity: associations with mortality in rheumatoid arthritis." *J Rheumatol* 35(6):945–9.
8. Symmons, D. P., and S. E. Gabriel. 2011. "Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE." *Nat Rev Rheumatol* 7(7):399–408.
9. Asklig, J., C. M. Fored, L. Brandt, E. Baecklund, L. Bertilsson, N. Feltelius, L. Coster, P. Geborek, L. T.
10. Costenbader, K. H., D. Feskanich, L. A. Mandl, and E. W. Karlson. 2006. "Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women." *Am J Med* 119(6):503 e1–9.
11. Farragher, T. M., N. J. Goodson, H. Naseem, A. J. Silman, W. Thomson, D. Symmons, and A. Barton. 2008. "Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis." *Arthritis Rheum* 58(2):359–69.
12. Mathey, D. L., W. Thomson, W. E. Ollier, M. Batley, P. G. Davies, A. K. Gough, J. Devlin, P. Prouse, D. W. James, P. L. Williams, J. Dixey, J. Winfield, N. L. Cox, G. Koduri, and A. Young. 2007. "Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study." *Arthritis Rheum* 56(5):1408–16.
13. Doll, R., R. Peto, J. Boreham, and I. Sutherland. 2004. "Mortality in relation to smoking: 50 years' observations on male British doctors." *BMJ* 328(7455):1519.
14. Warner, D. O. 2006. "Perioperative abstinence from cigarettes: physiologic and clinical consequences." *Anesthesiology* 104(2):356–67.
15. Rietbrock, N., S. Kunkel, W. Worner, and P. Eyer. 1992. "Oxygen-dissociation kinetics in the blood of smokers and non-smokers: interaction between oxygen and carbon monoxide at the hemoglobin molecule." *Naunyn Schmiedebergs Arch Pharmacol* 345(1):123–8.
16. Neaton, J. D., D. N. Wentworth, J. Cutler, J. Stamler, and L. Kuller. 1993. "Risk factors for death from different types of stroke. Multiple Risk Factor Intervention Trial Research Group." *Ann Epidemiol* 3(5):493–9.
17. Schwamm, L. H., G. C. Fonarow, M. J. Reeves, W. Pan, M. R. Frankel, E. E. Smith, G. Ellrodt, C. P. Cannon, L. Liang, E. Peterson, and K. A. Labresh. 2009. "Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack." *Circulation* 119(1):107–15.
18. Akrawi, W., and J. L. Benumof. 1997. "A pathophysiological basis for informed preoperative smoking cessation counseling." *J Cardiothorac Vasc Anesth* 11(5):629–40.
19. Ambrose, J. A., and R. S. Barua. 2004. "The pathophysiology of cigarette smoking and cardiovascular disease: an update." *J Am Coll Cardiol* 43(10):1731–7.

The Clinical Case for providing stop smoking support to Rheumatic Disease Patients

20. Moller, H., and H. Tonnesen. 1997. "Alcohol drinking, social class and cancer." *IARC Sci Publ* (138):251–63.
21. Zevin, S., and N. L. Benowitz. 1999. "Drug interactions with tobacco smoking. An update." *Clin Pharmacokinet* 36(6):425–38.
22. Shah, R. S., and J. W. Cole. 2010. "Smoking and stroke: the more you smoke the more you stroke." *Expert Rev Cardiovasc Ther* 8(7):917–32.
23. Soderlin, M. K., and S. Bergman. 2011. "Absent "Window of Opportunity" in Smokers with Short Disease Duration. Data from BARFOT, a Multicenter Study of Early Rheumatoid Arthritis." *J Rheumatol* 38(10):2160–68.
24. Westhoff, G., R. Rau, and A. Zink. 2008. "Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group." *Rheumatology (Oxford)* 47(6):849–54.
25. Rigotti, N. A., M. R. Munafo, and L. F. Stead. 2007. "Interventions for smoking cessation in hospitalised patients." *Cochrane Database Syst Rev* (3):CD001837.
26. Hoppe, B., and T. Dornier. 2008. "Is there a 'window of opportunity' for intervention to reduce risk of coronary artery disease in SLE?" *Nat Clin Pract Rheumatol* 4(9):452–3.
27. Anczakj, Nogler (2003) . Tobacco cessation in primary care: maximizing intervention strategies. *Clinical Medicine & Research* 2003; 1: 201–216
28. Fu S, Partin M, Snyder A, An LC, Nelson DB, Clothier B, Nugent S, Willenbring ML, Joseph AM. (2006) Promoting repeat tobacco dependence treatment: are relapsed smokers interested? *American Journal of managed Care* 2006; 12 235–243
29. Smoking Toolkit Study (2001) Available at: <http://www.smokinginengland.info/>
30. Slama KJ, Redman S, Cockburn J, Sanson-Fisher R. Community views about the role of general practitioners in disease prevention. *Family Practice* 1989; 6: 203–209.
31. Department of Health 2009. "Stop Smoking Interventions in secondary care." in www.dh.gov.uk/publications.
32. USDHHS. 1990. "How Tobacco Smoke Causes Disease. The Biology and Behavioural Basis for Smoking-Attributable Disease." in DHHS Publication No (CDC), edited by Centre for Disease Control for Chronic Disease Prevention and Health Promotion US Department of Health and Human Service, Office on Smoking and Health